Amgen, Inc. (AMGN) Holdings Cut by Bartlett & Co. LLC

Bartlett & Co. LLC lessened its position in Amgen, Inc. (NASDAQ:AMGN) by 1.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 285,753 shares of the medical research company’s stock after selling 3,635 shares during the period. Amgen accounts for 2.0% of Bartlett & Co. LLC’s investment portfolio, making the stock its 12th biggest position. Bartlett & Co. LLC’s holdings in Amgen were worth $49,692,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in AMGN. Blue Fin Capital Inc. boosted its stake in shares of Amgen by 1.0% during the 2nd quarter. Blue Fin Capital Inc. now owns 6,306 shares of the medical research company’s stock valued at $1,086,000 after purchasing an additional 65 shares in the last quarter. Pinnacle Financial Partners Inc. boosted its stake in shares of Amgen by 15.9% during the 2nd quarter. Pinnacle Financial Partners Inc. now owns 38,069 shares of the medical research company’s stock valued at $6,557,000 after purchasing an additional 5,226 shares in the last quarter. Rational Advisors LLC bought a new stake in shares of Amgen during the 2nd quarter valued at about $189,000. Conning Inc. boosted its stake in shares of Amgen by 13.9% during the 2nd quarter. Conning Inc. now owns 214,815 shares of the medical research company’s stock valued at $36,998,000 after purchasing an additional 26,144 shares in the last quarter. Finally, Donaldson Capital Management LLC boosted its stake in shares of Amgen by 1.8% during the 2nd quarter. Donaldson Capital Management LLC now owns 156,774 shares of the medical research company’s stock valued at $27,001,000 after purchasing an additional 2,827 shares in the last quarter. 78.03% of the stock is currently owned by institutional investors and hedge funds.

Shares of Amgen, Inc. (AMGN) opened at $186.67 on Friday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The company has a market cap of $135,510.00, a PE ratio of 16.97, a P/E/G ratio of 2.18 and a beta of 1.42. Amgen, Inc. has a 52 week low of $152.16 and a 52 week high of $201.23.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period last year, the firm posted $2.89 earnings per share. analysts expect that Amgen, Inc. will post 13.21 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be issued a $1.32 dividend. The ex-dividend date is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a yield of 2.83%. Amgen’s payout ratio is 48.00%.

Amgen declared that its Board of Directors has initiated a stock repurchase program on Thursday, February 1st that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

A number of equities research analysts have recently weighed in on AMGN shares. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $199.00 target price on the stock in a research note on Friday, October 27th. Citigroup lowered shares of Amgen to a “neutral” rating in a research note on Monday, December 18th. Argus raised shares of Amgen from a “hold” rating to a “buy” rating and lifted their target price for the company from $192.33 to $220.00 in a research note on Tuesday, January 23rd. Goldman Sachs Group lowered shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Finally, Mizuho set a $198.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Sunday, October 29th. Sixteen analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Amgen presently has an average rating of “Hold” and an average price target of $191.84.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 4,575 shares of company stock valued at $818,361 over the last ninety days. Corporate insiders own 0.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Amgen, Inc. (AMGN) Holdings Cut by Bartlett & Co. LLC” was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/02/24/amgen-inc-amgn-holdings-cut-by-bartlett-co-llc.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply